Fanconi syndrome associated with cidofovir therapy.
نویسندگان
چکیده
Cidofovir is a nucleoside analog with potent activity against cytomegalovirus (CMV); it is 10-fold more potent than ganciclovir in vitro (4). Its phosphorylated metabolite has an intracellular half-life greater than 48 h, and it is estimated that intracellular phosphorylated cidofovir may inhibit CMV replication for 5 to 10 days (1). The proposed maintenance treatment in patients presenting with CMV retinitis, a devastating AIDS-related opportunistic infection, consists of only one intravenous administration every 2 weeks, which is clearly attractive. However, experimental and preclinical studies have shown that cidofovir may induce tubular injuries (3). We report a case of Fanconi syndrome and acute renal failure which occurred in a patient with CMV retinitis while he received cidofovir. A 55-year-old human immunodeficiency virus-seropositive homosexual male suffered a relapse of CMV retinitis after a long period of intravenous ganciclovir maintenance administration. Serum creatinine was 108 mmol/liter, creatinine clearance was 71 ml/min/1.73 m, serum bicarbonate was 22 mmol/ liter, serum phosphore was 1.29 mmol/liter, and proteinuria glycosuria was undetectable. His daily treatment consisted of indinavir (800 mg three times a day), stavudine (40 mg twice a day), and sulfamethoxazole (400 mg)-trimethoprim (80 mg). A first injection of cidofovir (360 mg intravenously, 5 mg/kg of body weight) and a second one a week later were given in association with oral probenecid (4 g/day) and intravenous hydration (2 liters of 0.9% NaCl). A third injection (290 mg) was given without probenecid (stopped for an erythroderma). Before the third injection, serum creatinine clearance was 77 ml/min/1.73 m, serum bicarbonate was 19 mmol/liter, and serum phosphore was 0.5 mmol/liter. Acute renal failure associated with Fanconi syndrome without pain or fever was diagnosed 5 days later; serum creatinine was 415 mmol/liter, creatinine clearance was 18 ml/min/1.73 m, serum bicarbonate was 15 mmol/liter, serum phosphore was 2 mmol/liter, nonselective proteinuria was 2.7 g/liter, and glycosuria was 7.1 mmol/ liter. Renal echography was normal. A kidney biopsy revealed interstitial fibrosis and tubular necrosis affecting primarily the proximal convoluted tubules with partial loss of epithelial cells and denudation of the adjacent basement membranes. Four months later, renal failure remained (creatinine clearance, 33 ml/min/1.73 m), with mild glycosuria (4 mmol/liter) and proteinuria (1.2 g/liter). Cidofovir may induce a nephropathy in humans (2) that is characterized by degeneration and necrosis of the proximal convoluted tubule cells. Prevention of cidofovir nephrotoxicity includes hydration and probenecid treatment. Probenecid decreases the tubular secretion of cidofovir and limits nephrotoxicity in monkeys (3), but its efficacy in humans has not been established. In our patient, tubular injury preceded renal insufficiency. It occurred soon after the initiation of cidofovir treatment despite administration of probenecid with the first two injections. We strongly suggest that proximal tubular function be assessed (consisting at least of glycosuria and acidosis assessment) before each cidofovir administration in addition to the serum creatinine and proteinuria assessment recommended. The occurrence of any tubular toxicity even without alteration in renal function indicates that cidofovir treatment should be stopped. The efficacy of probenecid in our case is unclear; its use with the first injection of cidofovir did not prevent the onset of acidosis and hypophosphoremia, the first symptoms of tubular injury. The third injection of cidofovir without probenecid may have increased the nephrotoxicity of the drug. The possibility that indinavir, which was coadministered in our patient, enhanced cidofovir nephrotoxicity is not excluded. Indinavir nephrotoxicity has been recently reported (5). Finally, the efficacy and side effects of probenecid and indinavir coadministered with cidofovir remain to be determined through prospective studies.
منابع مشابه
A new case of Finnish-type congenital nephrotic syndrome, neuromuscular symptoms and early death
1. Sánchez-Conde M, Gil P, Sánchez-Somolinos M et al. Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin. HIV Clin Trials 2005; 6: 278–280 2. D’Ythurbide G, Goujard C, Méchaı̈ F et al. Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and lite...
متن کاملAbacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome.
There are several reports of Fanconi syndrome (FS) with or without nephrogenic diabetes insipidus (NDI) in patients with human immunodeficiency virus (HIV) infection, treated with various antiretroviral medications like cidofovir, adefovir, didenosine and tenofovir. But neither FS nor NDI has been documented with abacavir therapy. We are reporting the first case of abacavir-induced reversible F...
متن کاملگزارش یک مورد اسکواموس سل کارسینوما در یک زن جوان با سابقه آنمی فانکونی (Fanconi's anemia)
Fanconi syndrome was first described in 1927 by G.Fanconi. Fanconi syndrome with congenital aplastic anemia is a hereditary disorder in which peripheral blood Pancytopenia and bone marrow hypoplasiais often associated with multiple somatic congenital malformations such as microcephaly, skeletal anomalies (absence or hypoplasia of radial or thumb or both of them), brown hyperpigmentation of the ...
متن کاملHypotonic fluids should not be used in volume-depleted children.
To the Editor: We read with interest the excellent article of Daugas et al [1] on HAART-related nephropathies and we would like to clarify several points. There has been no case report of Fanconi syndrome (FS) related to reverse transcriptase inhibitors (RTIs) except one induced by didanosine [2]. Actually, the suspected case of nevirapine-induced FS was largely related to lactic acidosis rathe...
متن کاملFailure of cidofovir therapy in progressive multifocal leukoencephalopathy unrelated to human immunodeficiency virus.
We describe the first reported human immunodeficiency virus (HIV)-seronegative patient treated with cidofovir for progressive multifocal leukoencephalopathy (PML). Marked clinical and radiological progression of PML occurred during cidofovir therapy. The improvement observed during cidofovir therapy of HIV-infected patients may be due to the effect of concomitant antiretroviral therapy rather t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Antimicrobial agents and chemotherapy
دوره 41 8 شماره
صفحات -
تاریخ انتشار 1997